Clinical Trials
105 trialsNCT06946680 2026-05-22
Peds IMPACT
University of Florida
Phase 1 Not yet recruiting
NCT06838676 2026-05-15
ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
Nationwide Children's Hospital
Phase 2 Recruiting
NCT07589257 2026-05-15
A Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midline Glioma / Diffuse Intrinsic Pontine Glioma
Guangzhou Virotech Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT02359565 2026-05-13
Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT05096481 2026-05-11
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
Nationwide Children's Hospital
Phase 2 Recruiting
NCT04870944 2026-05-05
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Children's Oncology Group
Phase 1/2 Recruiting
NCT07076498 2026-05-05
Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care Radiation
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT04837547 2026-04-28
PEACH
University of Florida
Phase 1 Active not recruiting
NCT04099797 2026-04-27
C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)
Baylor College of Medicine
Phase 1 Recruiting
NCT05843253 2026-04-22
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Nationwide Children's Hospital
Phase 2 Recruiting
NCT04185038 2026-04-13
Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
Seattle Children's Hospital
Phase 1 Recruiting
NCT05278208 2026-04-13
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
Nationwide Children's Hospital
Phase 1/2 Recruiting
NCT06465199 2026-04-13
Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
Milton S. Hershey Medical Center
Phase 1/2 Recruiting
NCT07206849 2026-04-08
Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)
Nationwide Children's Hospital
Phase 2 Not yet recruiting
NCT03033992 2026-04-06
Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG
Children's Oncology Group
Phase NA Active not recruiting
NCT04978727 2026-04-06
A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Children's Oncology Group
Phase 1 Active not recruiting
NCT07501156 2026-03-30
H3K27M-specific Immune Effector Cells Targeting DMG/DIPG
Shenzhen Geno-Immune Medical Institute
Phase 1/2 Recruiting
NCT03605550 2026-03-27
A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma
Nationwide Children's Hospital
Phase 1 Active not recruiting
NCT03478462 2026-03-18
CLOVER-2
Cellectar Biosciences, Inc.
Phase 1 Active not recruiting
NCT04655404 2026-03-18
A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
Nationwide Children's Hospital
Phase EARLY_PHASE1 Recruiting
NCT04943848 2026-03-17
rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG
Ann & Robert H Lurie Children's Hospital of Chicago
Phase 1 Recruiting
NCT01165333 2026-03-16
CILENT
Centre Oscar Lambret
Phase 1 Completed
NCT06333899 2026-03-12
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
Nationwide Children's Hospital
Phase EARLY_PHASE1 Recruiting
NCT06639607 2026-03-10
PRiME II
Washington University School of Medicine
Phase 1/2 Not yet recruiting
NCT04238819 2026-03-02
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Eli Lilly and Company
Phase 1/2 Completed
NCT05476939 2026-02-05
BIOMEDE 2
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Recruiting
NCT05762419 2026-01-28
FUS Etoposide for DMG
Columbia University
Phase 1 Recruiting
NCT07331064 2026-01-09
GABRIEL
Medical College of Wisconsin
Phase 1 Not yet recruiting
NCT04049669 2026-01-08
Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
Augusta University
Phase 2 Active not recruiting
NCT05009992 2025-12-17
PNOC022
University of California, San Francisco
Phase 2 Recruiting
NCT05956821 2025-12-08
Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
University of Miami
Phase 1/2 Recruiting
NCT05768880 2025-11-20
Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors
Seattle Children's Hospital
Phase 1 Active not recruiting
NCT06521567 2025-11-12
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
GlaxoSmithKline
Phase 1/2 Active not recruiting
NCT03396575 2025-10-29
BRAVO
University of Florida
Phase 1 Terminated
NCT02742883 2025-09-16
A Study of Atengenal and Astugenal in Diffuse, Intrinsic Pontine Glioma (DIPG)
Burzynski Research Institute
Phase 2 Suspended
NCT03330197 2025-08-12
A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG
Alaunos Therapeutics
Phase 1/2 Terminated
NCT06624371 2025-07-22
AflacBT2303
Emory University
Phase 1 Recruiting
NCT04239092 2025-07-17
9-ING-41 in Pediatric Patients With Refractory Malignancies.
Actuate Therapeutics Inc.
Phase 1 Terminated
NCT03893487 2025-07-11
PNOC016
University of California, San Francisco
Phase EARLY_PHASE1 Active not recruiting
NCT04804709 2025-06-08
Non-Invasive Focused Ultrasound (FUS) With Oral Panobinostat in Children With Progressive Diffuse Midline Glioma (DMG)
Columbia University
Phase 1 Terminated
NCT04749641 2025-06-06
ENACTING
Beijing Tiantan Hospital
Phase 1 Completed
NCT03598244 2025-04-20
Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03690869 2025-04-08
REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma
Regeneron Pharmaceuticals
Phase 1/2 Terminated
NCT02420613 2025-04-02
Vorinostat and Temsirolimus With or Without Radiation Therapy in Treating Younger Patients With Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma
M.D. Anderson Cancer Center
Phase 1 Completed
NCT06221553 2025-03-30
CMD03DIPG
Chulalongkorn University
Phase 1 Recruiting
NCT02992015 2025-03-07
Gemcitabine in Newly-Diagnosed Diffuse Intrinsic Pontine Glioma
University of Colorado, Denver
Phase EARLY_PHASE1 Completed
NCT06161974 2025-02-21
Study of Olutasidenib and Temozolomide in HGG
Rigel Pharmaceuticals
Phase 2 Recruiting
NCT03416530 2025-02-14
ONC201 in Pediatric H3 K27M Gliomas
Jazz Pharmaceuticals
Phase 1 Terminated
NCT05298995 2025-02-05
GD2-CAR T Cells for Pediatric Brain Tumours
Bambino Gesù Hospital and Research Institute
Phase 1 Recruiting
NCT02960230 2025-01-22
H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas
University of California, San Francisco
Phase 1/2 Completed